LENSAR Appoints New CMO, Director; Updates Officer Compensation
Ticker: LNSR · Form: 8-K · Filed: May 8, 2024 · CIK: 1320350
| Field | Detail |
|---|---|
| Company | Lensar, Inc. (LNSR) |
| Form Type | 8-K |
| Filed Date | May 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $75 m, $100 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-changes, governance
Related Tickers: LNSR
TL;DR
LENSAR brings in a new CMO and adds a director to the board.
AI Summary
On May 3, 2024, LENSAR, Inc. announced the appointment of Dr. Jeffrey Spragens as Chief Medical Officer and the election of Ms. Laura L. E. Smith to its Board of Directors. Additionally, the company reported on its compensatory arrangements for certain officers.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member suggests strategic shifts and potential future direction for LENSAR's medical and corporate governance.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are standard corporate governance events.
Key Players & Entities
- LENSAR, Inc. (company) — Registrant
- Dr. Jeffrey Spragens (person) — Appointed Chief Medical Officer
- Ms. Laura L. E. Smith (person) — Elected to Board of Directors
FAQ
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 03, 2024.
Who has been appointed as the new Chief Medical Officer for LENSAR, Inc.?
Dr. Jeffrey Spragens has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors of LENSAR, Inc.?
Ms. Laura L. E. Smith has been elected to the Board of Directors.
What is the principal executive office address for LENSAR, Inc.?
The principal executive office is located at 2800 Discovery Drive, Orlando, Florida 32826.
What is the Commission File Number for LENSAR, Inc.?
The Commission File Number for LENSAR, Inc. is 001-39473.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-05-08 16:00:11
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share LNSR The Nasdaq Stock Mar
- $75 m — -year trailing revenues equal or exceed $75 million, and (ii) 50% if, as of any calen
- $100 million — -year trailing revenues equal or exceed $100 million. Name Number of RSUs Number of PS
Filing Documents
- lnsr-20240503.htm (8-K) — 39KB
- 0000950170-24-055579.txt ( ) — 149KB
- lnsr-20240503.xsd (EX-101.SCH) — 24KB
- lnsr-20240503_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LENSAR, Inc. Date: May 8, 2024 By: /s/ Nicholas T. Curtis Nicholas T. Curtis Chief Executive Officer